Compounds > sb 203580
Page last updated: 2024-09-05

sb 203580 and N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide

sb 203580 has been researched along with N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide in 1 studies

Compound Research Comparison

Studies
(sb 203580)		Trials
(sb 203580)		Recent Studies (post-2010)
(sb 203580)		Studies
(N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide)		Trials
(N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide)		Recent Studies (post-2010) (N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide)
3,48941,137804

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide (IC50)
Chain A, Protein tyrosine kinase 2 betaHomo sapiens (human)0.011
Chain A, Protein tyrosine kinase 2 betaHomo sapiens (human)0.011
Chain A, Protein tyrosine kinase 2 betaHomo sapiens (human)0.011
Androgen receptorRattus norvegicus (Norway rat)0.011
Focal adhesion kinase 1Homo sapiens (human)0.0013
Protein-tyrosine kinase 2-betaHomo sapiens (human)0.0294

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Munoz, L1

Reviews

1 review(s) available for sb 203580 and N-methyl-N-[2-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methanesulfonamide

ArticleYear
Non-kinase targets of protein kinase inhibitors.
    Nature reviews. Drug discovery, 2017, Volume: 16, Issue:6

    Topics: Animals; Drug Design; Drug Evaluation, Preclinical; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Kinases

2017